Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies

Publisher： Bentham Science Publishers

E-ISSN： 1874-4729|11|3|192-199

ISSN： 1874-4710

Source： Current Radiopharmaceuticals, Vol.11, Iss.3, 2018-12, pp. : 192-199

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Evolving Clinical Role of Actinium-225 and Bismuth-213 for Targeted Alpha Therapy (TAT) - Production, Radiopharmaceutical Development and Clinical Applications

By  

Current Radiopharmaceuticals, Vol. 11, Iss. 3, 2018-12 ,pp. : 154-155

Bentham Science Publishers

Access to resources Recommend Favorite

An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth

By  

Current Radiopharmaceuticals, Vol. 11, Iss. 3, 2018-12 ,pp. : 200-208

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical activity of tipifarnib in hematologic malignancies

By Jabbour Elias   Kantarjian Hagop   Cortes Jorge  

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 3, 2007-03 ,pp. : 381-392

Informa Healthcare

Access to resources Recommend Favorite

Immunotoxins in the Treatment of Hematologic Malignancies

By  

Current Drug Targets, Vol. 7, Iss. 10, 2006-01 ,pp. : 1301-1311

Bentham Science Publishers

Access to resources Recommend Favorite

Antiangiogenic Therapy in Hematologic Malignancies

By  

Current Pharmaceutical Design, Vol. 10, Iss. 11, 2004-04 ,pp. : 1221-1234

Bentham Science Publishers

Access to resources Recommend Favorite